Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology

Ono Pharmaceutical has signed an agreement with US biotechnology company Aitia to collaborate on drug discovery in neurological diseases. Aitia will use its platform to analyse clinical and omics data and construct digital models for predictions. Aitia uses its technology platform to discover new drug targets and biomarkers. Credit: PeopleImages / Shutterstock.com. Japan-based Ono Pharmaceutical has signed an agreement with US biotechnology company Aitia to collaborate on drug discovery in neurological diseases. The agreement will see Aitia apply its REFS technology to build Gemini Digital Twins (GDTs) of neurological conditions to identify potential new therapeutic targets and biomarkers. NPVM: AstraZeneca…

Source: Pharmaceutical Technology